- Home
- MGRX vs APM Comparison
MGRX vs APM Comparison
Compare MGRX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | APM |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.0M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MGRX | APM |
|---|---|---|
| Price | $0.39 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 21.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $615,873.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.65 |
| 52 Week High | $5.20 | $4.47 |
Technical Indicators
Market Signals| Indicator | MGRX | APM |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 44.39 |
| Support Level | $0.35 | $0.74 |
| Resistance Level | $0.69 | $1.11 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 14.07 | 42.99 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.